The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | The potential of bispecific antibodies in CLL
In this video, Parag Jasani, FRCPath, MBBS, MRCP, Royal Free London NHS Foundation Trust, London, UK, briefly discusses the potential of bispecific antibodies in chronic lymphocytic leukemia (CLL), highlighting that they may be a promising therapeutic option for patients with double-refractory disease. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, bispecific antibodies, as I’m sure people know, are up and coming therapeutic agents and they are widely used for lymphoma, particularly diffuse large B-cell lymphoma and also for multiple myeloma. We feel CLL is quite underserved and there’s not been that many advances with bispecific antibodies in CLL. There is a real unmet need for those patients who are double-refractory, who have refractory to BTKis and BCL2 inhibitors...
So, bispecific antibodies, as I’m sure people know, are up and coming therapeutic agents and they are widely used for lymphoma, particularly diffuse large B-cell lymphoma and also for multiple myeloma. We feel CLL is quite underserved and there’s not been that many advances with bispecific antibodies in CLL. There is a real unmet need for those patients who are double-refractory, who have refractory to BTKis and BCL2 inhibitors. So these bispecific antibodies provide a good option for these patients.
Bispecific antibodies are quite clever molecules and they’ve got two arms to it. One attaches to the CD3 cells and the other attaches to the tumor cells and causes synapse formation and activates the T-cell. So the T-cell activation is quite unique with the bispecific antibodies, very similar to CAR-T but slightly different.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
